Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety
Our study suggests that early 9-month EID after the third infusion is a safe and effective treatment option for MS patients.
Authors
- Hilde Marie Torgauten
- Øivind Torkildsen (ORCID: https://orcid.org/0000-0001-5294-2866)
- Magdalena Fossum (ORCID: https://orcid.org/0000-0002-6997-663X)
- Jan Harald Aarseth (ORCID: https://orcid.org/0009-0004-8443-2261)
- Kristin Wesnes (ORCID: https://orcid.org/0000-0002-0918-8367)
- Kjell‐Morten Myhr (ORCID: https://orcid.org/0000-0002-0980-510X)
- Maryam Shirzadi
- Stig Wergeland (ORCID: https://orcid.org/0000-0002-7645-7686)
- Lars Bø (ORCID: https://orcid.org/0000-0001-8675-4433)
Institutions
- Norwegian University of Science and Technology (NO)
- Haukeland University Hospital (NO)
- St Olav's University Hospital (NO)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1016/j.msard.2025.106400
- Citations
- 4
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.89
Funders
- Norges Teknisk-Naturvitenskapelige Universitet
- Universitetet i Bergen